Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782057 | 0.89 | P2RX7 (0.39) | P2RX7KITFLT3FLT4KDR | |
| SCHEMBL2811328 | 0.87 | MEN1 (0.40) | P2RX7DDX3XAURKA | |
| SCHEMBL2805177 | 0.84 | P2RX7 (0.35) | P2RX7TRPV1FLT4DDX3XAURKA | |
| SCHEMBL2806336 | 0.82 | P2RX7 (0.34) | P2RX7TRPV1FLT4DDX3XNAMPT | |
| SCHEMBL13128609 | 0.82 | BDKRB1 (0.38) | P2RX7DHODHDDX3XAURKA | |
| SCHEMBL2782634 | 0.80 | MEN1 (0.39) | P2RX7FLT4KDRDDX3XAURKA | |
| SCHEMBL2805697 | 0.79 | RAB9A (0.41) | P2RX7TRPV1MAPT | |
| SCHEMBL2807472 | 0.79 | P2RX7 (0.39) | P2RX7AURKA | |
| SCHEMBL13160219 | 0.78 | P2RX7 (0.32) | P2RX7KITFLT3 | |
| Hydrochloric Acid SCHEMBL2805225 | 0.78 | P2RX7 (0.39) | P2RX7AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | P2RX7 30/4885KIT 989/4885FLT3 632/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | P2RX7 30/4885KIT 989/4885FLT3 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.